

"TEMPUS

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

May 5, 2025

CHICAGO--(BUSINESS WIRE)--May 5, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of [Notetaker](#), an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in [Tempus Hub](#), ambly records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records.

Notetaker complements Tempus' existing mental health platform designed to support clinicians in delivering personalized care. It joins other precision medicine solutions, including the [Tempus nP pharmacogenomic test](#) and [PRO™](#), the company's patient reported outcome solution.

Key features of Notetaker include:

- **Recording Sessions:** Notetaker effortlessly transcribes and processes the session in real-time, capturing key details with precision, including specialized psychiatric terminology and medications.
- **Generating Notes:** At the end of each session, a clinical note is automatically created, highlighting essential information such as symptoms, progress, and action plans for quick review.
- **Refining During Review:** Clinicians can easily review and modify the autogenerated note using the Magic Edit features to adjust formatting or details according to their preferences.
- **Care Gap Notification:** Notetaker identifies and helps close care gaps with real-time pharmacogenomic insights for medications under consideration.

"We are excited to enhance our mental health platform with Notetaker, a tool built by clinicians, for clinicians, and thoughtfully designed to meet the unique demands of psychiatric care," said Dr. Muneer Ali, Senior Director of Medical Affairs, Neurology and Psychiatry, at Tempus. "Notetaker eases the burden of clinical documentation, helping providers reclaim their time and streamline their workflow so they can focus on what matters most: their patients."

Notetaker is capable of understanding more than 30 languages, including English, Spanish, and Chinese. It can seamlessly recognize language switching without the need to set a specific language in advance. With adjustable settings tailored for telehealth, in-person sessions, and dictation, Notetaker adapts to various environments for adequate audio capture. While providers are responsible for obtaining all necessary consents before recording sessions, Notetaker supports HIPAA-compliant data transfer and storage.

To get started with Notetaker, please visit: www.tempus.com/notetaker

For more information on Tempus' Neurology and Psychiatry platform, please visit: <https://www.tempus.com/neurology-psychiatry/>

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Notetaker and other AI-solutions in supporting clinical care and administrative efficiency. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-Q for the fiscal quarter ended

December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250505730127/en/): <https://www.businesswire.com/news/home/20250505730127/en/>

Hanah Heintzelman
hanah.heintzelman@tempus.com

Source: Tempus AI, Inc.